Outcomes of transfemoral-transcatheter aortic valve replacement with Sapien-3 valve in liver cirrhosis patients

Abstract Background Little is known about the outcomes of liver cirrhosis patients with severe aortic stenosis (AS) who undergo transcatheter valve replacement (TAVR). Methods We undertook a retrospective analysis consecutive symptomatic AS underwent transfemoral-TAVR Sapien-3 at our Clinic between April 2015 and December 2018, yielding 32 on imaging including ultrasound and/or computed tomography. Their baseline characteristics, procedural long-term after TAVR non-cirrhotic group were compared, along their management strategies as per hepatology team. Results Among 1028 patients, assigned to cirrhosis, 996 non-cirrhosis (control) group. Compared control cirrhotic slightly younger in age (74.5 vs 81.2 years), had higher BMI (31.3 29.3), incidence prior history myocardial infarction (38% 33%). Baseline variables smoking, hypertension, diabetes, atrial fibrillation comparable both groups. (n=32), most common etiologies non-alcoholic steatohepatitis (NASH) (37.5%), Alcoholism (18.75%), Hepatitis C (12.5%). The mean MELD-NA score was 11.8 67% Child PUGH Class A 33% B all ≥5. 53% (n=17) evaluated by Hepatology 12.5% (n=4) for transplant but only 1 patient post-TAVR. similar 1-year mortality (12% 12%, p=1), lower rate 30-day new pacemaker post tavr (6% 9% p=0.85), readmission heart failure 5% p=0.12) major adverse cardiac cerebrovascular event (MACCE) (15% 14% p=0.98) Conclusion Patients undergoing concomitant demonstrate compared non- counterparts. NASH followed alcoholic found be etiology. Funding Acknowledgement Type funding sources: None. Figure 1Figure 2